F Stephen Hodi

Author PubWeight™ 243.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
2 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009 24.11
3 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
4 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 14.71
5 High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007 12.68
6 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
7 Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015 7.51
8 Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008 5.95
9 Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012 5.32
10 Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010 5.23
11 BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013 4.28
12 Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008 3.58
13 Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013 3.51
14 CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013 3.02
15 Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res 2012 2.68
16 The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2012 2.63
17 KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008 2.57
18 From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012 2.46
19 Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003 2.36
20 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
21 Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014 2.12
22 Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013 2.03
23 Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013 1.91
24 Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 2006 1.88
25 Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005 1.87
26 Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res 2010 1.83
27 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 1.80
28 Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008 1.73
29 Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2013 1.67
30 Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013 1.65
31 Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med 2015 1.64
32 Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 2008 1.63
33 Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003 1.61
34 Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013 1.53
35 A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J 2014 1.51
36 The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013 1.46
37 Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013 1.44
38 Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 2007 1.44
39 Mutation-driven drug development in melanoma. Curr Opin Oncol 2010 1.43
40 Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 2011 1.37
41 Melanoma. J Natl Compr Canc Netw 2009 1.37
42 Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008 1.34
43 Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002 1.31
44 When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012 1.28
45 Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013 1.23
46 Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013 1.22
47 Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003 1.14
48 Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2013 1.11
49 Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013 1.09
50 The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 2012 1.09
51 Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist 2013 1.08
52 Melanoma, version 4.2014. J Natl Compr Canc Netw 2014 1.07
53 Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014 1.05
54 Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 2010 1.05
55 Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 2013 1.03
56 Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013 1.03
57 Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther 2012 1.03
58 Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016 1.02
59 Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011 1.02
60 Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015 0.98
61 Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One 2013 0.97
62 Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol 2011 0.96
63 Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res 2011 0.94
64 Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res 2005 0.93
65 Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res 2015 0.92
66 MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun 2003 0.92
67 Melanoma. J Natl Compr Canc Netw 2012 0.90
68 Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol 2015 0.89
69 c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res 2012 0.89
70 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
71 Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res 2008 0.87
72 Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol 2008 0.86
73 Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother 2011 0.86
74 The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol 2014 0.86
75 Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol 2012 0.85
76 Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother 2005 0.84
77 Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002 0.81
78 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
79 Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol 2010 0.79
80 Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging 2014 0.78
81 Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol 2016 0.77
82 Treatment for advanced melanoma: new drugs, new opportunities, new challenges. Oncology (Williston Park) 2013 0.75
83 Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm. N Engl J Med 2007 0.75